| BRK confers tamoxifen-resistance in breast cancer via regulation of tyrosine phosphorylation of CDK1. | BRK confers tamoxifen-resistance in breast cancer via regulation of tyrosine phosphorylation of CDK1.
Mandapati A, Ning Z, Baharani A, Lukong KE. | 06/22/2023 |
| Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk. | Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk.
Kan Y, Paung Y, Kim Y, Seeliger MA, Miller WT., Free PMC Article | 03/26/2023 |
| PTK6 inhibits autophagy to promote uveal melanoma tumorigenesis by binding to SOCS3 and regulating mTOR phosphorylation. | PTK6 inhibits autophagy to promote uveal melanoma tumorigenesis by binding to SOCS3 and regulating mTOR phosphorylation.
Liu B, Yao X, Zhang C, Liu Y, Wei L, Huang Q, Wang M, Zhang Y, Hu D, Wu W., Free PMC Article | 01/28/2023 |
| Interference of PTK6/GAB1 signaling inhibits cell proliferation, invasion, and migration of cervical cancer cells. | Interference of PTK6/GAB1 signaling inhibits cell proliferation, invasion, and migration of cervical cancer cells.
Li J, Yang N, Tian X, Ouyang L, Jiang M, Zhang S., Free PMC Article | 08/6/2022 |
| Breast Tumour Kinase (Brk/PTK6) Contributes to Breast Tumour Xenograft Growth and Modulates Chemotherapeutic Responses In Vitro. | Breast Tumour Kinase (Brk/PTK6) Contributes to Breast Tumour Xenograft Growth and Modulates Chemotherapeutic Responses In Vitro.
Burmi RS, Box GM, Wazir U, Hussain HA, Davies JA, Court WJ, Eccles SA, Jiang WG, Mokbel K, Harvey AJ., Free PMC Article | 05/7/2022 |
| Prognostic value of protein tyrosine kinase 6 overexpression in cancers: a meta-analysis. | Prognostic value of protein tyrosine kinase 6 overexpression in cancers: a meta-analysis.
Jeong SY, Kim JH, Lee JJ, Park ST, Kim HS. | 04/30/2022 |
| Targeting protein tyrosine kinase 6 in cancer. | Targeting protein tyrosine kinase 6 in cancer.
Gilic MB, Tyner AL., Free PMC Article | 01/23/2021 |
| BRK competitively binds and phosphorylates SMAD4 and regulates transforming growth factor-beta/SMAD4 signaling pathway. Activated BRK-mediated degradation of SMAD4 is associated with the repression of tumor suppressor gene FRK and increased expression of mesenchymal markers, SNAIL, and SLUG. | BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential.
Miah S, Banks CAS, Ogunbolude Y, Bagu ET, Berg JM, Saraf A, Tettey TT, Hattem G, Dayebgadoh G, Kempf CG, Sardiu M, Napper S, Florens L, Lukong KE, Washburn MP., Free PMC Article | 05/30/2020 |
| PSPC1, a nuclear substrate of PTK6, sequesters PTK6 in the nucleus and loses its metastasis driving capability in hepatocellular carcinoma. Conversely, PSPC1 upregulation or PSPC1-Y523F mutation promotes epithelial-mesenchymal transition, stemness, and metastasis via cytoplasmic translocation of active PTK6 and nuclear translocation of beta-catenin, which interacts with PSPC1 to augment Wnt3a autocrine signaling. | PSPC1-interchanged interactions with PTK6 and β-catenin synergize oncogenic subcellular translocations and tumor progression.
Lang YD, Chen HY, Ho CM, Shih JH, Hsu EC, Shen R, Lee YC, Chen JW, Wu CY, Yeh HW, Chen RH, Jou YS., Free PMC Article | 04/4/2020 |
| Using saturation transfer difference NMR and molecular docking, we demonstrate that vemurafenib binds in the active site of PTK6, inhibiting its activation. These structural studies provide insight into the PTK6-vemurafenib complex, which can be utilized for further refinement chemistry, whereas functional studies demonstrate that active PTK6 is a viable drug target in prostate cancer | Vemurafenib Inhibits Active PTK6 in PTEN-null Prostate Tumor Cells.
Wozniak DJ, Hitchinson B, Gilic MB, Bie W, Gaponenko V, Tyner AL., Free PMC Article | 03/28/2020 |
| Study provides evidence that BRK is regulated by ERalpha signaling in ER-positive breast cancer cells. Overall survival of ER-positive breast cancer patients is poor when their cancers express high levels of BRK. These data indicate that BRK is a prognostic marker for ER+ breast cancers. | Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
Miah S, Bagu E, Goel R, Ogunbolude Y, Dai C, Ward A, Vizeacoumar FS, Davies G, Vizeacoumar FJ, Anderson D, Lukong KE., Free PMC Article | 05/4/2019 |
| Identification of STAT3 as a specific substrate of breast tumor kinase. | Identification of STAT3 as a specific substrate of breast tumor kinase.
Liu L, Gao Y, Qiu H, Miller WT, Poli V, Reich NC. | 04/22/2019 |
| The PTK6 plays a tumor suppressor role in laryngeal squamous cell carcinoma (LSCC) by regulating c-myc and cyclinD1 expression, cell apoptosis, EMT and MMP-9. | Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma.
Wu D, Zhang X, Liu Z, Yan H, Mai J, Zhao Z, Zhong Q, Liu X. | 02/23/2019 |
| Using small molecule inhibitors, findings suggest that the kinase activity of PTK6 does not play a significant role in breast tumorigenesis. | Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Qiu L, Levine K, Gajiwala KS, Cronin CN, Nagata A, Johnson E, Kraus M, Tatlock J, Kania R, Foley T, Sun S., Free PMC Article | 12/22/2018 |
| In prostate tumor tissue microarrays, loss of PTEN phosphohydrolase (PTEN) correlates with increased tyrosine kinase 6 PTK6 tyrosine 342 (PY342) phosphorylation and poor outcome. | PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer.
Wozniak DJ, Kajdacsy-Balla A, Macias V, Ball-Kell S, Zenner ML, Bie W, Tyner AL., Free PMC Article | 10/6/2018 |
| These results indicate that plasma-membrane-associated PTK6 phosphorylates Eps8, which promotes cell proliferation, adhesion, and migration | PTK6 Localized at the Plasma Membrane Promotes Cell Proliferation and MigratiOn Through Phosphorylation of Eps8.
Shin WS, Shim HJ, Lee YH, Pyo M, Park JS, Ahn SY, Lee ST. | 12/23/2017 |
| Expression of PTK6 in established tumors may maintain the epithelial phenotype, preventing tumor progression. | Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer.
Mathur PS, Gierut JJ, Guzman G, Xie H, Xicola RM, Llor X, Chastkofsky MI, Perekatt AO, Tyner AL., Free PMC Article | 10/14/2017 |
| analysis of recombinant PTK6 kinase domain by x-ray crystallography reveals details of its binding to inhibitors | Co-crystal structures of PTK6: With Dasatinib at 2.24 Å, with novel imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 Å resolution.
Thakur MK, Birudukota S, Swaminathan S, Battula SK, Vadivelu S, Tyagi R, Gosu R. | 06/10/2017 |
| The crystal structure of the kinase domain of human PTK6 has been reported. | Crystal structure of the kinase domain of human protein tyrosine kinase 6 (PTK6) at 2.33 Å resolution.
Thakur MK, Kumar A, Birudukota S, Swaminathan S, Tyagi R, Gosu R. | 06/3/2017 |
| PTK6 mRNA and protein levels were elevated in cervical squamous cell cancer and the elevated cytoplasmic expression of PTK6 was associated with tumor grade and short patient survival. | The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer.
Wang XJ, Xiong Y, Ma ZB, Xia JC, Li YF., Free PMC Article | 03/18/2017 |
| PELP1 interacted with GR to activate Brk expression. | Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
Regan Anderson TM, Ma SH, Raj GV, Cidlowski JA, Helle TM, Knutson TP, Krutilina RI, Seagroves TN, Lange CA., Free PMC Article | 07/30/2016 |
| PTK6 prolongs S-phase and increases the ability of gemcitabine to cause DNA damage in vitro and in vivo | PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
Ono H, Basson MD, Ito H. | 06/11/2016 |
| BRK expression in a majority of CC can interact with RTK, augmenting growth and interfering with proliferation inhibitors (SAM68). Therapeutically targeting BRK function (in addition to RTK) should be of benefit for CC treatment. | Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.
Mizuguchi Y, Specht S, Isse K, Sasatomi E, Lunz JG 3rd, Takizawa T, Demetris AJ. | 05/28/2016 |
| Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression | Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
Falkenberg N, Anastasov N, Höfig I, Bashkueva K, Lindner K, Höfler H, Rosemann M, Aubele M., Free PMC Article | 02/20/2016 |
| overexpression or knockdown of PTK6 or ERK1/2 effectively removed the inhibition of S1P-induced migration by miR-17. | Sphingosine-1-phosphate induces the migration of thyroid follicular carcinoma cells through the microRNA-17/PTK6/ERK1/2 pathway.
Zhao S, Li J., Free PMC Article | 01/16/2016 |